カレントテラピー　30-7　サンプル page 15/30

このページは カレントテラピー　30-7　サンプル の電子ブックに掲載されている15ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
経口薬とGLP-1受容体作動薬の作用機序と治療のエビデンスproperties and tissue selectivity. Diabetes Res Clin Pract66：S75-78, 200412）Shigeto M, Katsura M, Matsuda M, et al：Nateglinide andmitiglinide, b....

経口薬とGLP-1受容体作動薬の作用機序と治療のエビデンスproperties and tissue selectivity. Diabetes Res Clin Pract66：S75-78, 200412）Shigeto M, Katsura M, Matsuda M, et al：Nateglinide andmitiglinide, but not sulfonylureas, induce insulin serectionthrough a mechanism mediated by calcium release fromendoplasmic reticulum. J Pharmacol Exp Ther 322：1 -7,200713）McKillop AM, Duffy NA, Lindsay JR, et al：Insulinotropicactions of nateglinide in type 2 diabetic patients and effectson dipeptidyl peptidase -Ⅳactivity and glucose -dependentinsulinotropic polypeptide degradation. Eur J Endocrinol161：877-885, 200914）Maedler K, Carr RD, Bosco D, et al：Sulfonylurea inducedβcell apoptosis in cultured human islets. J Clin EndocrinolMetab 90：501-506, 200515）Mine T, Miura K, Kajioka T, et al：Suppressive Effect ofNateglinide on High Fat Diet-induced Hepatic Accumulationof Triglycerides in Goto-Kakizaki Rats. Prog Med 25：1125 -1132, 200516）Boni -Schnetzler M, Thorne J, Parnaud G, et al：Increasedinterleukin（IL）-1beta messenger ribonucleic acid expressionin beta -cells of individuals with type 2 diabetes and regulationof IL -1beta in human islets by glucose and autostimulation.J Clin Endocrinol Metab 93：4065-4074, 200817）Satoh J, Takahashi K, Takizawa Y, et al：Secondary sulfonylureafailure：comparison of period until insulin treatmentbetween diabetic patients treated with gliclazide and glibenclamide.Diabetes Res Clin Pract 70：291 -297, 200518）Nathan DM, Buse JB, Davidson MB, et al；AmericanDiabetes Association；European Association for Study ofDiabetes：Medical management of hyperglycemia in type 2diabetes：a consensus algorithm for the initiation and adjustmentof therapy：a consensus statement of the AmericanDiabetes Association and European Association for the Studyof Diabetes. Diabetes Care 32：193 -203, 200919）Holman RR, Paul SK, Bethel MA, et al：10-year follow-up ofintensive glucose control in type 2 diabetes. N Engl J Med359：1577-1589, 200820）Patel A, MacMahon S, Chalmers J, et al；ADVANCECollaborative Group：Intensive blood glucose control andvascular outcomes in patients with type 2 diabetes. N Engl JMed 358：2560-2572, 200821）Holman RR, Haffner SM, McMurray JJ, et al；The NAVIGA-TOR Study Group：Effect of Nateglinide on the incidence ofdiabetes and cardiovascular events. N Engl J Med 362：1463 -1476, 201022）日本糖尿病学会編：糖尿病治療ガイド2012 -2013．p46 -47,文光堂，東京，201223）日本糖尿病学会編：糖尿病専門医研修ガイドブック改訂第5版．p121，診断と治療社，東京，2012Current Therapy 2012 Vol.30 No.762939